logo
#

Latest news with #PlatformSupportGrants

UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research
UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research

Malaysian Reserve

time13-06-2025

  • Health
  • Malaysian Reserve

UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research

VANCOUVER, BC, June 13, 2025 /CNW/ – UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation. The two newly funded platforms are: International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for Grant Awarded: $1,866,750 The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain Grant Awarded: $4,845,000 'This platform represents a critical step toward advancing spinal cord injury research globally,' said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. 'By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients.' 'With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience,' said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. 'By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments.' These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders. 'The UBC neuroscience community is grateful for Brain Canada's continued support,' said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. 'These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan.' Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: 'By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives.' These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. 'Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries,' said the Honourable Marjorie Michel, Minister of Health. 'Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes.'

UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research
UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research

Yahoo

time13-06-2025

  • Health
  • Yahoo

UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research

VANCOUVER, BC, June 13, 2025 /CNW/ - UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation. The two newly funded platforms are: International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for Grant Awarded: $1,866,750 The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain Grant Awarded: $4,845,000 "This platform represents a critical step toward advancing spinal cord injury research globally," said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. "By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients." "With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience," said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. "By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments." These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders. "The UBC neuroscience community is grateful for Brain Canada's continued support," said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. "These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan." Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: "By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives." These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. "Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries," said the Honourable Marjorie Michel, Minister of Health. "Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes." SOURCE Brain Canada View original content to download multimedia:

UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research Français
UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research Français

Cision Canada

time13-06-2025

  • Health
  • Cision Canada

UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research Français

VANCOUVER, BC, June 13, 2025 /CNW/ - UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation. The two newly funded platforms are: International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for patients. Total Grant Awarded: $1,866,750 The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain disorders. Total Grant Awarded: $4,845,000 "This platform represents a critical step toward advancing spinal cord injury research globally," said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. "By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients." "With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience," said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. "By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments." These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders. "The UBC neuroscience community is grateful for Brain Canada's continued support," said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. "These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan." Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: "By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives." These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. "Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries," said the Honourable Marjorie Michel, Minister of Health. "Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes."

Brain Canada Invests in Expansion of National Neuromuscular Disease Registry to Advance Patient-Centered Research Français
Brain Canada Invests in Expansion of National Neuromuscular Disease Registry to Advance Patient-Centered Research Français

Cision Canada

time27-05-2025

  • Health
  • Cision Canada

Brain Canada Invests in Expansion of National Neuromuscular Disease Registry to Advance Patient-Centered Research Français

CALGARY, AB, May 27, 2025 /CNW/ - Brain Canada is investing in transformative research platforms across the country to accelerate neuroscience discovery and improve outcomes for people living with brain-related conditions. As part of this national initiative, Dr. Lawrence Korngut at the University of Calgary has been awarded a 2024 Platform Support Grant (PSG) of $553,660 to expand the Canadian Neuromuscular Disease Registry (CNDR) into a multi-modal, open science platform. "By expanding the CNDR, we're deepening our understanding of the lived experience of people with neuromuscular disorders. This evolution not only supports the development of better treatments but also ensures that patient voices are reflected in the data that drives discovery." — Dr. Lawrence Korngut, University of Calgary "This audacious national effort reflects Brain Canada's commitment to a culture of open science grounded in transparency, collaboration, and increased access to shared resources, services, facilities and more." — Dr. Viviane Poupon, President and CEO of Brain Canada. The Platform Support Grants program is a cornerstone of Brain Canada's strategy to strengthen the country's neuroscience and mental health research infrastructure. By supporting shared platforms, including databases, biobanks, specialized equipment, and research facilities, the program enables collaboration, accelerates discovery, and expands access to cutting-edge tools to Canadian scientists. The ambitious task of studying the brain calls for integrated and collaborative research platforms. By funding these platforms, we are building a foundation that Canadian researchers will use to strengthen the future of all neuroscience and mental health research. Brain Canada is committed to fostering a culture of open science through transparency and collaboration. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. Over the coming weeks, Brain Canada will unveil the full list of 14 research platforms selected to receive PSG funding. The total investment of $36.8 million represents a major step forward in Canada's ability to support cutting-edge brain research and improve outcomes for people living with brain-disorders. The Canadian Neuromuscular Disease Registry (CNDR) supports research and tracks the effectiveness of treatments for neuromuscular disorders (NMDs), which are rare and complex conditions that affect nerves and muscles. By collecting data from over 40 clinics with more that 5,800 patients across Canada and collaborating with over 130 researchers, the CNDR has become an extensive network for standardized data collection and a valuable resource for advancing research in NMDs. Integrating patient-reported outcome measures into its various registries, including a new one for fascioscapulohumeral muscular dystrophy (FSHD), to capture severity and quality of life more frequently, will improve our understanding of the lived experience of people with NMDs and add depth to CNDR data across all diseases.

Brain Canada Invests in Expansion of National Neuromuscular Disease Registry to Advance Patient-Centered Research
Brain Canada Invests in Expansion of National Neuromuscular Disease Registry to Advance Patient-Centered Research

Yahoo

time27-05-2025

  • Business
  • Yahoo

Brain Canada Invests in Expansion of National Neuromuscular Disease Registry to Advance Patient-Centered Research

CALGARY, AB, May 27, 2025 /CNW/ - Brain Canada is investing in transformative research platforms across the country to accelerate neuroscience discovery and improve outcomes for people living with brain-related conditions. As part of this national initiative, Dr. Lawrence Korngut at the University of Calgary has been awarded a 2024 Platform Support Grant (PSG) of $553,660 to expand the Canadian Neuromuscular Disease Registry (CNDR) into a multi-modal, open science platform. "By expanding the CNDR, we're deepening our understanding of the lived experience of people with neuromuscular disorders. This evolution not only supports the development of better treatments but also ensures that patient voices are reflected in the data that drives discovery." — Dr. Lawrence Korngut, University of Calgary "This audacious national effort reflects Brain Canada's commitment to a culture of open science grounded in transparency, collaboration, and increased access to shared resources, services, facilities and more." — Dr. Viviane Poupon, President and CEO of Brain Canada. The Platform Support Grants program is a cornerstone of Brain Canada's strategy to strengthen the country's neuroscience and mental health research infrastructure. By supporting shared platforms, including databases, biobanks, specialized equipment, and research facilities, the program enables collaboration, accelerates discovery, and expands access to cutting-edge tools to Canadian scientists. The ambitious task of studying the brain calls for integrated and collaborative research platforms. By funding these platforms, we are building a foundation that Canadian researchers will use to strengthen the future of all neuroscience and mental health research. Brain Canada is committed to fostering a culture of open science through transparency and collaboration. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. Over the coming weeks, Brain Canada will unveil the full list of 14 research platforms selected to receive PSG funding. The total investment of $36.8 million represents a major step forward in Canada's ability to support cutting-edge brain research and improve outcomes for people living with brain-disorders. About The Platform: Expanding CNDR as an Open Science, Multi-modal Data Platform: Dr. Lawrence Korngut, University of Calgary Total grant amount: $553,660.00 The Canadian Neuromuscular Disease Registry (CNDR) supports research and tracks the effectiveness of treatments for neuromuscular disorders (NMDs), which are rare and complex conditions that affect nerves and muscles. By collecting data from over 40 clinics with more that 5,800 patients across Canada and collaborating with over 130 researchers, the CNDR has become an extensive network for standardized data collection and a valuable resource for advancing research in NMDs. Integrating patient-reported outcome measures into its various registries, including a new one for fascioscapulohumeral muscular dystrophy (FSHD), to capture severity and quality of life more frequently, will improve our understanding of the lived experience of people with NMDs and add depth to CNDR data across all diseases. SOURCE Brain Canada View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store